Drug intelligence / Profile preview

MPB-1514

Development stage: Phase 2
Lead developer: MegaPro Biomedical
Modality: Small Molecules, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

MPB-1514 is a non-sugar, PEG-coated intravenous iron formulation developed for the treatment of iron deficiency anemia. Its design allows for high macrophage phagocytic efficiency and rapid conversion to transferrin-bound iron, facilitating effective red blood cell production. The PEG coating aims to improve safety and reduce hypersensitivity reactions compared to other intravenous iron products. MPB-1514 enables higher dosing with fewer injections, improving patient compliance. Developed by MegaPro Biomedical, it has completed Phase I clinical trials in Taiwan and reached Phase II in the United States[1][2][3][8].

Brand names: iop injection
Other names: mpb-1514mpb1514mpb 1514iop injection

Beyond the preview

Go deeper on MPB-1514.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MPB-1514.

Explore the full profile